Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial

J Am Acad Dermatol. 2022 Jun;86(6):1398-1401. doi: 10.1016/j.jaad.2021.05.047. Epub 2021 Jun 2.

¹ Henry Ford Medical Center, Detroit, Michigan. Electronic address: IHamzavi@hamzavi.com.
² Tufts Medical Center, Boston, Massachusetts.
³ University of Massachusetts Medical School, Worcester, Massachusetts.
⁴ Palo Alto Foundation Medical Group, Mountain View, California; University of Texas Southwestern Medical Center, Dallas, Texas.
⁵ Icahn School of Medicine at Mount Sinai, New York, New York.
⁶ Incyte Corporation, Wilmington, Delaware.
⁷ The Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California.

No abstract available

Publication types